Asset Details
Do you wish to reserve the book?
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
Do you wish to request the book?
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
2022
Overview
Immune checkpoint inhibitors (ICIs) show efficacy in the treatment of non-Hodgkin lymphomas (NHL). However, these agents are associated with a unique group of side effects called immune-related adverse events (irAEs). We conducted an observational retrospective/prospective study on patients with relapsed/refractory NHL treated with ICI to determine the incidence of irAEs assessing the type, severity, and timing of onset, outcome and relationship with study drugs of these events. Thirty-two patients underwent ICI as single agent (N = 20) or in combination (N = 12). Ten patients (31.3%) developed at least one irAE for a total of 17 irAEs. Median time to presentation of irAEs was 69 days (range 0–407) with a median resolution time of 16 days (range 0–98). Progression free survival at 24 months for patients who developed an irAE was 40% and 31.8% for who did not. Overall survival for the two groups did not differ (at 24 months 40.0% and 62.5% for patients without and with irAE, respectively), but the median for who developed an irAE was not reached. The incidence of irAEs was associated with better long-term survival in NHL treated with ICIs but patients’ disease conditions need to be carefully evaluated to decide the optimal management.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/308
/ Adult
/ Diabetes
/ Drug-Related Side Effects and Adverse Reactions
/ Ethics
/ Female
/ Humanities and Social Sciences
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - adverse effects
/ Immune Checkpoint Inhibitors - pharmacology
/ Immune System Diseases - etiology
/ Immunotherapy - adverse effects
/ Ligands
/ Lymphoma
/ Lymphoma, Non-Hodgkin - drug therapy
/ Lymphoma, Non-Hodgkin - immunology
/ Male
/ Patients
/ Science
/ Survival
